Does Metformin Extend Lifespan in Humans?
No direct evidence shows metformin extends human lifespan. The drug, used for type 2 diabetes, lowers blood glucose and improves insulin sensitivity, but large trials like UKPDS and DPP report no overall mortality benefit beyond diabetes control.[1][2] Observational studies hint at lower cardiovascular death rates in diabetic users versus non-users, yet these can't prove causation due to confounding factors like healthier lifestyles among treated patients.[3]
What Animal Studies Show
Metformin extends lifespan in worms (C. elegans) by 40-50% via AMPK activation and mitochondrial effects, mimicking calorie restriction.[4] In mice, results vary: it boosts median lifespan in some strains (e5% in females) but shortens it in others or shows no effect on maximum lifespan.[5] Rodent data suggests metabolic benefits like reduced cancer and inflammation, but translation to humans remains uncertain.
Why Researchers Test It for Longevity
Metformin's appeal stems from mechanisms overlapping calorie restriction: AMPK/mTOR inhibition, reduced IGF-1 signaling, gut microbiome shifts, and anti-inflammatory effects.[6] The TAME trial (Targeting Aging with Metformin), a planned six-year study of 3,000 non-diabetics aged 65-79, aims to measure composite aging endpoints like heart disease or dementia onset, not direct lifespan.[7] If positive, it could support FDA reclassification as an anti-aging drug.
Does It Work for Healthy People?
No randomized data exists for non-diabetics pursuing longevity. Short-term trials show metabolic improvements (e.g., slight weight loss, better insulin sensitivity), but long-term risks include B12 deficiency, lactic acidosis (rare, <1/100,000), and potential muscle loss.[8][9] Healthy users often self-experiment off-label, but experts like Nir Barzilai argue benefits may only apply to those with insulin resistance.
Key Risks and Who Should Avoid It
Common side effects: gastrointestinal issues (nausea, diarrhea in 20-30%). Rare but serious: lactic acidosis in kidney impairment. Long-term use links to 10-30% higher B12 deficiency risk, potentially worsening neuropathy or cognition.[10] Avoid if eGFR <30, heavy alcohol use, or heart failure. Consult a doctor; it's prescription-only.
When Might We Know More?
TAME recruitment stalled due to funding (needs $75M); results, if funded, expected post-2030.[7] Meanwhile, competitors like rapamycin show stronger mouse lifespan data but higher side effects. Metformin remains cheap ($4/month generic) and accessible, driving interest despite evidence gaps.
Sources
[1] UK Prospective Diabetes Study (UKPDS) Group, Lancet (1998). https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)07037-8/fulltext
[2] Diabetes Prevention Program Research Group, NEJM (2002). https://www.nejm.org/doi/full/10.1056/NEJMoa012512
[3] Bannister et al., Diabetes, Obesity and Metabolism (2014). https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.12300
[4] Onken & Driscoll, PLoS One (2010). https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0008756
[5] Strong et al., Aging Cell (2013). https://onlinelibrary.wiley.com/doi/10.1111/acel.12000
[6] Barzilai et al., Cell Metabolism (2016). https://www.cell.com/cell-metabolism/fulltext/S1550-4131(16)30251-3
[7] Justice et al., Aging Cell (2018). https://onlinelibrary.wiley.com/doi/10.1111/acel.12796 (TAME details)
[8] Aroda et al., Diabetes Care (2016). https://diabetesjournals.org/care/article/39/11/1927/37200
[9] Lalau et al., Diabetes Care (2011). https://diabetesjournals.org/care/article/34/8/1796/29849
[10] de Jager et al., BMJ (2010). https://www.bmj.com/content/340/bmj.c2181